The change pattern and significance of IgM and IgG in the progress of COVID-19 disease

Xuzhen Qin, Jun Shen, Erhei Dai, Haolong Li, Guodong Tang, Lixia Zhang, Xin Hou, Minya Lu, Xian Wu, Simeng Duan, Jingjia Zhang, Yongzhe LimedRxiv 2020 · DOI

Abstract

This study investigates the kinetics and clinical significance of IgM and IgG antibodies during the progression of COVID-19. Utilizing a multicenter cross-sectional study of 571 patients and a longitudinal cohort study of 30 patients across four Chinese hospitals, the research maps the immune response from symptom onset. Results indicate that 91.9% of confirmed cases were IgG positive and 92.3% were IgM positive. Longitudinal tracking revealed that IgM levels peak at approximately day 10, while IgG levels peak around day 20. Furthermore, antibody titers and positive rates were found to correlate with disease severity and the duration of infection. These findings provide a framework for interpreting serological tests and predicting disease prognosis, particularly as a supplement to nucleic acid testing.

Introduction

During the initial stages of the COVID-19 pandemic, nucleic acid (PCR) testing served as the primary diagnostic tool. However, clinicians frequently encountered high false-negative rates due to low viral loads in the upper respiratory tract, unstandardized sampling techniques, or the natural decline of viral shedding after the first week of illness.

While serological (antibody) tests were developed to address these diagnostic gaps, early clinical application was hindered by a lack of data regarding the "window phase"—the interval between infection and a detectable immune response. This research seeks to define the temporal kinetics of IgM and IgG antibodies and determine whether antibody concentrations can serve as biomarkers for disease severity.

Methodology

The researchers implemented a dual-study design to capture both broad prevalence and specific temporal changes:

  1. Multicenter Cross-Sectional Study: Data from 571 patients (235 confirmed SARS-CoV-2 infections and 336 suspected cases) were collected from four major hospitals in China (Beijing, Tianjin, Wuhan, and Shijiazhuang). This allowed for an analysis of antibody prevalence across different clinical stages.
  2. Cohort Study: A subset of 30 confirmed patients from Tianjin was followed for 20 days to track the longitudinal rise and fall of antibody concentrations.

Antibody levels were measured using chemiluminescence or immuno-chromatographic assays. Patients were stratified by clinical classification (light, normal, heavy, and critical) and by the time elapsed since symptom onset (≤7 days, 8–15 days, and >15 days).

Key Insights into Antibody Kinetics

The "Window Phase" and Diagnostic Timing

The study highlights the critical nature of the diagnostic window. Before day 7 of symptom onset, the seroprevalence of IgM and IgG was approximately 81% and 83%, respectively. However, after 15 days, the IgG positive rate reached nearly 100%. This confirms that while serological testing is a powerful diagnostic aid, its reliability is highest approximately two weeks after the appearance of symptoms.

The IgM and IgG Transition

The cohort study identified a distinct temporal "hand-off" between antibody types. IgM, the early-phase responder, typically peaks around the 10th day following symptom onset before beginning a gradual decline. In contrast, IgG, which provides longer-term immune memory, overtakes IgM concentrations after day 15 and continues to rise through at least day 20.

Correlation with Disease Severity

A significant finding of this research is the relationship between antibody titers and clinical outcomes. Higher concentrations of both IgM and IgG were observed in patients classified as "heavy" or "critical" compared to those with "light" or "normal" symptoms. This suggests that a more robust—and potentially overactive—immune response is associated with increased disease severity. Additionally, patients in severe categories tended to be older, reinforcing age as a primary risk factor for progression.

Results and Diagnostic Implications

  • Sensitivity: In confirmed infections, the sensitivity for both IgG (91.9%) and IgM (92.3%) was high.
  • Specificity and False Positives: Among suspected patients who ultimately tested negative for the virus, 2.1% showed IgG positivity and 5.4% showed IgM positivity. These false positives are likely due to cross-reactivity with other viral infections, underlying malignancies, or autoimmune diseases. Consequently, antibody tests should be viewed as a supplement to, rather than a replacement for, PCR testing.
  • Innate Immunity: Approximately 8% of confirmed patients remained antibody-negative throughout the study. The authors hypothesize that in these individuals, the innate immune system may have successfully cleared the viral load before the adaptive immune system was fully triggered.

Limitations and Future Directions

While the study provides a roadmap for serological interpretation, several limitations remain:

  • Subgroup Sample Size: Certain clinical categories, particularly "light" cases, had very low enrollment (n=1), limiting the statistical power for those specific comparisons.
  • Asymptomatic Carriers: The study focused on symptomatic patients; the antibody kinetics of asymptomatic individuals remain unmapped in this dataset.
  • Neutralization: The assays measured total binding antibodies. It is not yet clear if high IgG titers correlate directly with neutralizing capability or long-term immunity.

Future research is required to determine the long-term persistence of IgG antibodies beyond the 20-day window and to evaluate the immune response in larger, more diverse populations, including asymptomatic carriers.

Summary updated

Abstract

Background To investigate the significance of IgM and IgG in the progress of COVID-19. Method A multicenter cross-sectional study conducted in suspected and confirmed patients from four hospitals of China and a cohort study to identify the change pattern and significance in the process of COVID-19 disease. Results A total of 571 patients were enrolled in the cross-sectional study, including 235 confirmed SARS-CoV-2 infection with 91.9% patients IgG positive and 92.3% IgM positive. 30 patients diagnosed with SARS-CoV-2 infection were enrolled in the cohort study for flowing-up in 20 days. The peak of IgM and IgG reached in 10 th and 20 th day separately after symptom onset. The relationship between clinical classification and serological antibodies were analysed. The positive rate of COVID-19 IgG and IgM increased along with the clinical classification and the delay of treatment time. Conclusion We demonstrated the kinetics of IgM and IgG SARS-CoV-2 antibody in COVID-19 patients, which may contribute to explain the results of IgM and IgG SARS-CoV-2 antibody test and predict the prognosis of COVID-19.
BibTeX
@misc{qin2020change,
  author = {Xuzhen Qin and Jun Shen and Erhei Dai and Haolong Li and Guodong Tang and Lixia Zhang and Xin Hou and Minya Lu and Xian Wu and Simeng Duan and Jingjia Zhang and Yongzhe Li},
  title = {{The change pattern and significance of IgM and IgG in the progress of COVID-19 disease}},
  year = {2020},
  doi = {10.1101/2020.07.20.20157446},
  howpublished = {medRxiv},
}
Figure